GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
0.639
-0.046 (-6.76%)
At close: Nov 20, 2024, 4:00 PM
0.636
-0.003 (-0.45%)
Pre-market: Nov 21, 2024, 7:03 AM EST
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2023. The number of employees increased by 3 or 300.00% compared to the previous year.
Employees
4
Change (1Y)
3
Growth (1Y)
300.00%
Revenue / Employee
n/a
Profits / Employee
-$2,065,750
Market Cap
1.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4 | 3 | 300.00% |
| Dec 31, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 84 |
| iCoreConnect | 70 |
| cbdMD | 52 |
| Sonnet BioTherapeutics Holdings | 12 |
| Phio Pharmaceuticals | 9 |
| Shuttle Pharmaceuticals Holdings | 8 |
| Dermata Therapeutics | 8 |
| Aclarion | 6 |
GRI News
- 6 days ago - GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 4 weeks ago - GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 - GlobeNewsWire
- 4 weeks ago - GRI Bio Announces Exercise of Warrants - GlobeNewsWire
- 5 weeks ago - GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) - GlobeNewsWire
- 7 weeks ago - GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions - GlobeNewsWire
- 2 months ago - GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment - GlobeNewsWire
- 2 months ago - GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - GRI Bio to Present at the 2024 European Respiratory Congress - GlobeNewsWire